ReviewEuropean archives of psychiatry and clinical neuroscience2013
Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors.
Review in European archives of psychiatry and clinical neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 53 citations in OpenAlex.
- Mapping Neurochemical Signatures onto Brain Structure for Neurotransmitter-Informed Discrimination of Schizophrenia Patients from Healthy Controls.medRxiv : the preprint server for health sciences · 2025Article
- Epigenetics and suicidal behavior in adolescents: a critical review.Epigenomics · 2025Review
- Pharmacological Interventions for Negative Symptoms in Schizophrenia: A Systematic Review of Randomised Control Trials.Biomedicines · 2025Review
- Review
- Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention.Frontiers in cellular neuroscience · 2022Review
- Review
- Epigenetic regulation of motivated behaviors by histone deacetylase inhibitors.Neuroscience and biobehavioral reviews · 2019Review
- A translational perspective on histone acetylation modulators in psychiatric disorders.Psychopharmacology · 2018Review
- GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia.Acta pharmacologica Sinica · 2018Review
- The epigenomics of schizophrenia, in the mouse.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2017Review
- The Nuclear Proteome of White and Gray Matter from Schizophrenia Postmortem Brains.Molecular neuropsychiatry · 2017Article
- Spatial genome organization and cognition.Nature reviews. Neuroscience · 2016Review
- Oral acetate supplementation attenuates N-methyl D-aspartate receptor hypofunction-induced behavioral phenotypes accompanied by restoration of acetyl-histone homeostasis.Psychopharmacology · 2016Article
- Prader-Willi Syndrome: The Disease that Opened up Epigenomic-Based Preemptive Medicine.Diseases (Basel, Switzerland) · 2016Review
- Converging models of schizophrenia--Network alterations of prefrontal cortex underlying cognitive impairments.Progress in neurobiology · 2015Review
- Kraepelin revisited: schizophrenia from degeneration to failed regeneration.Molecular psychiatry · 2015Review
- Epigenetic signaling in psychiatric disorders: stress and depression.Dialogues in clinical neuroscience · 2014Review
- Epigenetic mechanisms in schizophrenia.Dialogues in clinical neuroscience · 2014Review
- Modeling heterogeneous patients with a clinical diagnosis of schizophrenia with induced pluripotent stem cells.Biological psychiatry · 2014Review
- Visualizing epigenetics: current advances and advantages in HDAC PET imaging techniques.Neuroscience · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Notwithstanding the considerable advances in the treatment options for schizophrenia, the cognitive symptoms in particular are not receptive to antipsychotic treatment and considered one of the main predictors for poor social and functional outcome of the disease. Recent findings in preclinical model systems indicate that epigenetic modulation might emerge as a promising target for the treatment of cognitive disorders. The aim of this review is to introduce some of the principles of chromatin biology to the reader and to discuss a possible role in the neurobiology and pathophysiology of schizophrenia. We will discuss potential epigenetic targets for drug therapy, including histone deacetylase inhibitors (HDACi). In a second part, conceptual and practical challenges associated with clinical trials of chromatin-modifying drugs in psychiatric patient populations are discussed, including safety profiles, the potential for adverse effects and general issues revolving around pharmacokinetics and pharmacodynamics. Additional investigations are required in order to fully evaluate the potential of HDACi and similar "epigenetic therapies" as novel treatment options for schizophrenia and other psychotic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.